Key Highlights
● The roughly 1.1% decline on September 9, 2026 has no single, verifiable public catalyst; at this price and market size, small moves are ordinary.
● Headquartered in Rehovot, Israel, and listed on both the Nasdaq and the Tel Aviv Stock Exchange, Evogene has historically been a computational biology platform company spanning agriculture, human health and industrial applications.
● Evogene is a micro-cap, trading near $0.50 with a market Capitalization of roughly $7 million on about 13.5 million shares outstanding, within a 52-week range of about $0.37 to $1.50.
● Investors have several developments to monitor.
Company and Latest Development
Evogene Ltd (NASDAQ:EVGN) Headquartered in Rehovot, Israel, and listed on both the Nasdaq and the Tel Aviv Stock Exchange, Evogene has historically been a computational biology platform company spanning agriculture, human health and industrial applications. Through 2025 and 2026 it has pursued what management describes as a strategic transformation into a focused, AI-driven computational chemistry business, anchored by its ChemPass AI platform for small-molecule discovery. The company has cited collaborations intended to validate that pivot, including work with Google Cloud, Tel Aviv University, and a Partnership with South Korean biotech ELEO on a PCSK9 inhibitor program, signaling a deliberate tilt toward AI-enabled drug discovery.
What Is Driving Attention Around EVGN?
The roughly 1.1% decline on September 9, 2026 has no single, verifiable public catalyst; at this price and market size, small moves are ordinary. What has kept Evogene in focus is a combination of its AI repositioning and a governance dispute. Proxy advisory firms ISS and Glass Lewis recommended that shareholders support management's slate of director nominees against dissident investors, including L.I.A. Pure Capital and Invest-Pro, a contest reflected in multiple Schedule 13D amendment filings with the SEC. That fight over board control, rather than the day's trading, is the more meaningful backdrop.
Key Numbers and Company Position
Evogene is a micro-cap, trading near $0.50 with a market capitalization of roughly $7 million on about 13.5 million shares outstanding, within a 52-week range of about $0.37 to $1.50. Full-year 2025 Revenue was approximately $3.85 million, down about 31% from the prior year, and trailing revenue has fallen further as the Business narrows its focus. The company reported a net loss for 2025 of roughly $8.5 million and disclosed first-half 2026 results in a Form 6-K filed July 31, 2026, while pointing to year-over-year improvement in its quarterly loss. In June 2026 it filed a prospectus supplement tied to a securities offering, underscoring ongoing funding activity.
What Could Come Next?
Investors have several developments to monitor. The outcome of the Shareholder vote on board composition could shape strategy and capital allocation. Progress on the AI computational chemistry pivot, including milestones from the ELEO PCSK9 collaboration and any new ChemPass AI partnerships, would help validate the new direction. Given the small cash base, additional financing steps are likely and would be a key item to watch, as would any move to address the sub-$1 share price and Nasdaq listing requirements.
Risks to Watch
The risks are considerable. Evogene generates minimal revenue and remains lossmaking, and its transformation into computational chemistry is unproven commercially. The sub-$1 share price raises the risk of Nasdaq minimum bid price compliance issues. Reliance on Equity offerings creates dilution risk for existing holders, and the activist campaign introduces governance uncertainty. As a dual-listed foreign issuer with a tiny market capitalization, the shares are volatile and speculative, and collaboration-driven programs carry the usual scientific and partnership execution risk.
Evogene Ltd's Near-Term Catalysts Now Matter
Evogene's small September pullback is best read as routine micro-cap Volatility rather than a reaction to fresh news. The developments that matter for EVGN are the resolution of its boardroom contest, tangible traction for its AI-driven computational chemistry strategy and the ChemPass AI platform, and how it manages funding and Nasdaq listing compliance. Investors may be watching the shareholder vote, partnership milestones and the company's cash position closely in the months ahead.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...